US10213487 — Nasal powder formulation for treatment of hypoglycemia
Method of Use · Assigned to Eli Lilly and Co · Expires 2036-02-16 · 10y remaining
What this patent protects
This patent protects a nasal powder formulation containing glucagon or a glucagon analog for treating severe hypoglycemia.
USPTO Abstract
The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.
Drugs covered by this patent
- Glucagen (GLUCAGON) · Xeris
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2604 |
— | Glucagen |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.